Full-Time

Program Manager

Updated on 8/23/2026

Integer Holdings Corporation

Integer Holdings Corporation

1,001-5,000 employees

Medical device CDMO for cardiac devices

Compensation Overview

$137k - $202k/yr

+ Cash-based incentive program + 401(k) matching contributions

No H1B Sponsorship

Plymouth, MN, USA

In Person

Domestic and international travel may be required, up to 30% at times.

Bachelor's, Master's

Category
Business & Strategy (1)
Required Skills
Forecasting
Risk Management

Get referred to Integer Holdings Corporation

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Engineering or a related technical field.
  • At least 7 years of experience, including at least 4 years in a regulated product environment such as medical devices, pharmaceuticals, automotive, or aerospace and 3 years in project management with responsibility for multiple projects and project teams.
  • Demonstrated ability to lead team activities.
  • Strong ability to coach.
  • Advanced critical-thinking and problem-solving skills.
  • Strong communication, presentation, follow-through, and organizational skills.
  • Ability to work effectively vertically, horizontally, and cross-functionally across the organization.
  • Collaboration and conflict-resolution skills.
  • Knowledge of current Food and Drug Administration, International Organization for Standardization, Medical Device Directive, and related quality and regulatory system requirements intersecting with design control and product development.
  • Comprehension of product and process development engineering principles sufficient to participate in product and technology development program ideation, scoping, initiation, and execution.
  • Broad experience with manufacturing processes across multiple products and processes.
  • Ability to travel domestically and internationally as required.
Responsibilities
  • Manage and execute multiple projects of varying complexities from setup through completion.
  • Set up and regularly update projects in the Oracle enterprise resource planning system.
  • Forecast projects accurately and ensure adherence to customer agreements, billing events, and milestones.
  • Track project finances according to cost-management and revenue-recognition standards for nonrecurring engineering and sales of sample, prototype, or verification units.
  • Complete assigned projects within budget and on time while meeting performance objectives, resolving issues, and managing project and scope changes.
  • Plan, develop, and direct product-development and engineering projects from inception through implementation and handoff.
  • Prepare, monitor, and ensure adherence to master project and development plans, quotes, budgets, specifications, and schedules.
  • Establish key performance indicators and milestones for project governance and provide organization, leadership, and guidance to project and program teams.
  • Serve as the primary escalation point for assigned projects and respond to project-related service or information requests.
  • Prepare for and participate in internal and external status meetings and provide project updates to management, customers, and suppliers.
  • Identify and recommend improvements to Program and Project Management Office tools and share best practices across stakeholders and PMO functions.
  • Manage planning and communication with marketing, quality, regulatory, design assurance, and manufacturing functions for project initiatives and policies.
  • Resolve project issues and risks in the interests of customers, patients, internal customers, affiliated functions, and the business.
  • Support the commercial team in assessing new opportunities and developing quotes, including visits to customer or supplier sites when needed.
  • Engage with and support adherence to the Product Development Process, Manufacturing Transfer Process, and Technical Development Process.
  • Provide mentoring and training to associates within cross-functional teams and others as required.
  • Manage up to 2 to 3 direct reports, establish their goals and objectives, and support their personal and professional development plans.
  • Perform other assigned duties.
Desired Qualifications
  • Master’s degree in business or a technical field.
  • Certification in project or program management from an accredited institution.
  • Experience with manufacturing processes involving medical components, subassemblies, and finished medical devices.
Integer Holdings Corporation

Integer Holdings Corporation

View

Integer Holdings Corporation is a large medical device contract development and manufacturing organization (CDMO) that supports medical device makers in cardiac rhythm management, neuromodulation, and cardiovascular markets. It provides end-to-end services from design support to manufacturing, delivering components and finished subsystems such as implants, housings, electrodes, and batteries through its Greatbatch Medical, Lake Region Medical, and Electrochem brands. The company differentiates itself by its scale, breadth of capabilities across multiple medical specialties, established brand portfolio, and global manufacturing footprint that enable reliable, integrated supply. Its goal is to improve patients’ lives worldwide by helping customers bring safe and effective medical technologies to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

1940

Get referred to Integer Holdings Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 3, 2026 KKR deal prices Integer at $127, a 51.8% premium.
  • Second-quarter 2026 revenue hit $464.1 million and adjusted EPS reached $1.60.
  • KKR promised capacity, technology, and talent investment, plus employee ownership after closing.

What critics are saying

  • KKR closing slips past year-end 2026 if antitrust or stockholder votes fail.
  • Halper Sadeh's August 2026 investigation fuels litigation over fairness and disclosure.
  • New Ross shutdown exposed demand volatility and labor pain; repeat interruptions threaten margins and credibility.

What makes Integer Holdings Corporation unique

  • Integer's 2026 KKR sale confirms sticky device-manufacturing scale and regulatory know-how.
  • Its CDMO footprint serves interventional cardiology, neuromodulation, and orthopedics across global customers.
  • New Ross and other plants give Integer specialized capacity competitors cannot quickly replicate.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Adoption Assistance

Parental Leave

401(k) Company Match

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Company News

Yahoo Finance
Aug 16th, 2026
Healthcare stocks outpace S&P 500 by 13 percentage points over six months

Healthcare stocks have returned 26.1% over the past six months, outperforming the S&P 500 by 13.1 percentage points. However, investors must remain cautious due to heavy regulation affecting earnings potential. Integer Holdings faces concerns with 6.1% annual revenue growth over two years, lagging healthcare peers. Its modest revenue base of $1.84 billion provides less fixed cost leverage than larger competitors. The company trades at $125.07 per share, or 18.6 times forward price-to-earnings. Evolent Health shows weak platform performance and declining returns on capital. Its high net-debt-to-EBITDA ratio of 7 times could force unfavourable capital raises if market conditions worsen. Shares trade at $4.15, representing 12.4 times forward price-to-earnings. Tenet Healthcare, operating hospitals and surgical centres across nine US states, emerges as the recommended healthcare investment.

Yahoo Finance
Aug 4th, 2026
Integer Holdings acquired by KKR for $5.7B in all-cash deal at $127 per share

Integer Holdings agreed to be acquired by private equity firm KKR in an all-cash deal valued at approximately $5.7 billion. The transaction values the medical technology company at $127 per share. Shares jumped 2.7% in afternoon trading, continuing a rally from the previous session when the stock surged over 20% following the announcement. The acquisition news overshadowed strong second-quarter results, where Integer posted an adjusted profit of $1.60 per share on $464.1 million in revenue, surpassing analyst estimates. Following the buyout announcement, Integer withdrew its previously issued financial guidance and cancelled its upcoming earnings conference call. Shares traded at $124.50, marking a new 52-week high.

BizWire Express
Aug 3rd, 2026
KKR to acquire Integer for $5.7B in all-cash deal at $127 per share

KKR has agreed to acquire Integer Holdings Corporation, a medical device contract development and manufacturing organisation, in an all-cash transaction valued at approximately $5.7 billion. Integer stockholders will receive $127 per share, representing a 51.8% premium to the company's closing share price on 29 April 2026. The acquisition follows a comprehensive strategic review announced by Integer in April 2026. The Integer Board unanimously approved the agreement and recommends stockholder approval. KKR plans to invest in Integer's capacity, technology, innovation, and talent. The firm also intends to establish a broad-based employee ownership programme following the transaction's close, consistent with its approach across portfolio companies. The transaction is expected to close by year-end, subject to stockholder approval and regulatory clearances. Upon completion, Integer will become privately held and delist from the New York Stock Exchange.

Yahoo Finance
Aug 3rd, 2026
Integer Holdings beats Q2 expectations with $464M revenue and $1.60 earnings per share

Integer Holdings Corp. reported second-quarter net income of $23.6 million, or 69 cents per share. Adjusted earnings came to $1.60 per share, exceeding Wall Street expectations of $1.38 per share. The Plano, Texas-based medical device outsource manufacturer posted revenue of $464.1 million for the period, also beating analyst forecasts of $452.5 million. The results surpassed predictions from five analysts surveyed by Zacks Investment Research on both earnings and revenue metrics.

Financial Modeling Prep
Aug 3rd, 2026
KKR & Co Inc (NYSE: KKR) Acquires Integer Holdings Corporation (NYSE: ITGR): key insights into the medical device acquisition.

KKR & Co Inc (NYSE: KKR) Acquires Integer Holdings Corporation (NYSE: ITGR): key insights into the medical device acquisition. Aug 03, 2026 Market News FMPKKR & Co Inc (NYSE: KKR) Acquires Integer Holdings Corporation (NYSE: ITGR):... * Integer Holdings Corporation (NYSE: ITGR) is being acquired by KKR (NYSE: KKR) for approximately $5.70 billion at $127.00 per share. * The acquisition price represents a 51.80% premium over Integer's closing price on April 29, 2026. * An investor rights law firm, Halper Sadeh LLC, is investigating the acquisition to ensure a fair price for shareholders and compliance with federal securities laws. Integer Holdings Corporation is a leading medical-device outsourcing company. It helps other companies develop and manufacture medical devices. On August 3, 2026, global investment firm KKR announced it will acquire Integer in a deal valued at an enterprise value of approximately $5.70 billion. An analyst at Truist Financial (NYSE: TFC) set a new price target for Integer at $127.00. This price target directly matches the $127.00 per share all-cash offer made by KKR for the acquisition. The acquisition follows a strategic review process conducted by Integer's board of directors. The analyst also downgraded the stock to a "Hold" rating. A "Hold" rating suggests that the stock's price is not expected to move much. This is common after an acquisition announcement, as the stock price tends to stay close to the agreed-upon purchase price until the deal is finalized. The $127.00 per share offer is a 51.80% premium over Integer's closing price on April 29, 2026. It is also a 28.80% premium to the 30-day volume-weighted average price (VWAP) as of July 31, 2026. VWAP is the average price a stock has traded at over a period, adjusted for trading volume. Despite the premium, an investor rights law firm, Halper Sadeh LLC, is investigating the sale. As highlighted by Business Wire, the firm is looking into whether Integer's board secured a fair price for its shareholders and followed federal securities laws during the process. Market news and analyst rating coverage Rayan Ahmad covers market news, analyst rating changes, and company developments for the FMP blog. His work focuses on summarizing price-target updates, earnings results, and broker actions into accessible, data-backed market updates. Financial data for every need. Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions - all accessible via API. Stock Screener 2017-2026 (C) FMP